Post-earnings recap
Reported
Wed, Feb 11, 2026
EPS actual
$-0.65
EPS est.
$-0.06
EPS surprise
-1008.60%
1-day move
-1.20%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ascendis Pharma reported a significant loss in earnings per share, which contributed to a 1.2% decline in stock price. The lack of revenue figures and guidance leaves investors with limited insight into the company's future performance. The substantial EPS miss indicates potential challenges ahead for the company.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.65 | N/A | -1008.60% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.